CompletedPhase 2NCT03148275
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Studying Epithelioid hemangioendothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Scott M Schuetze, MD, PhDUniversity of Michigan Comprehensive Cancer Center EDDOP
- Intervention
- Questionnaire Administration(other)
- Enrollment
- 44 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2017 – 2023
Study locations (30)
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas Clinical Research Center, Fairway, Kansas, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03148275 on ClinicalTrials.govOther trials for Epithelioid hemangioendothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07104331SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid HemangioendotheliomaSarcoma Alliance for Research through Collaboration
- RECRUITINGPHASE1NCT06452160A Study of BGC515 Capsules in Subjects With Advanced Solid TumorsBridGene Biosciences Inc.
- RECRUITINGNCT06408441The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano